A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system
Int. Journal of Clinical Pharmacology and Therapeutics · 2024
DOI: 10.5414/cp204518 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Min Song und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Hyperprolactinemia, Antipsychotic Agents, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Song, M., Li, D., Peng, J., Wang, N., Zhang, M., & Ren, X. L. (2024). A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204518
Vancouver
Song M, Li D, Peng J, Wang N, Zhang M, Ren XL. A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204518
BibTeX
@article{Song2024,
author = {Song, Min and Li, Dong and Peng, Jing and Wang, Na and Zhang, Mei and Ren, Xiao-Lei},
title = {A disproportionality analysis of antipsychotic-induced hyperprolactinemia based on FDA adverse event reporting system},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.5414/cp204518}
}
EUVIMED